Information for the Media

Biotechnology / Life Sciences

Crowdfunding triggers Capital Increase of 800,000 Euros at Rodos Biotarget

After his initial crowd investment, medical entrepreneur and business angel Otto H. Gies invests in the biopharmaceutical company via direct shareholding.

Hannover, 17 August 2017. Rodos Biotarget is the first German life-science company to initiate crowdfunding campaigns via two crowd platforms. In 2016, a first round took place with Seedmatch, and a current financing round is running with aescuvest. With this approach, in addition to raising capital for further corporate development, Rodos Biotarget has two further objectives:

First, impact investing in the area of health economy will be opened up also for private investors within their bounds of possibilities. Second, the company wants to access business partners, collaborators, customers, and private equity through the level of attention created by crowdfunding. This has been achieved with the company entry of medical entrepreneur Otto H. Gies.

Over almost 30 years, managing partner Otto H. Gies developed the 3B Scientific company group into a specialty provider offering educational materials for medical training in more than one hundred countries. The company group was recently sold to an American private equity company, Otto H. Gies on his investment: “Rodos Biotarget’s new nanomedicine developments for addressing diabetes as well as various liver diseases in particular have convinced me.” Dr. Marcus Furch, Rodos’ managing partner, commented: “With Mr. Gies we are happy to having been able to win over an experienced entrepreneur with a valuable international network. We are greatly looking forward to working closely together with him.” This financing round is further accompanied by High-Tech Gründerfonds and Hannover Investimpuls Fonds.

About Rodos Biotarget GmbH
Rodos Biotarget GmbH (a limited liability company according to German law) has developed a platform technology called TargoSphere® for nanocarrier-enabled targeted and efficient drug delivery. This technology is suitable for prophylactic and therapeutic applications in various disease areas of high medical need. These include cancers, chronic infections, autoimmune diseases, and neurological disorders. For commercializing its patented technology platform, the company primarily relies on collaborations with major pharmaceutical companies. In addition, the company promotes in-house therapy developments including TargoBiotics™ for the treatment of intracellular bacterial infections, TargoVir™ for the treatment of chronic viral diseases, and further nanomedicines for the treatment of type 2 diabetes and liver diseases such as acute liver failure, liver fibrosis, urea cycle deficiencies and liver cancer.

Online Presence: http://www.biotargeting.eu

Contact Information
Dr. Marcus Furch, MBA
CEO / Managing Director
Tel.: +49 (511) 72738835
Fax: +49 (511) 2147076
m.furch@biotargeting.eu

Rodos Biotarget GmbH
Medical Park Hannover
Feodor-Lynen-Str. 31
D-30625 Hannover / Germany